Evidence map›Paper›PMID 29766031›Full record

ArticleMolecular therapy. Methods & clinical development2018

A Rationally Engineered Capsid Variant of AAV9 for Systemic CNS-Directed and Peripheral Tissue-Detargeted Gene Delivery in Neonates.

Dan Wang, Shaoyong Li, Dominic J Gessler, Jun Xie, Li Zhong, Jia Li, Karen Tran, Kim Van Vliet, Lingzhi Ren, Qin Su and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Methods & clinical development, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.

0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

51 citing papers in PubMed, 77 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Gene-sized editing for the therapy of genetic diseases.Functional & integrative genomics · 2026
    Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Advances in AAV capsid engineering: Integrating rational design, directed evolution and machine learning.Molecular therapy : the journal of the American Society of Gene Therapy · 2025
    Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 2 countries.

Dan WangHorae Gene Therapy Center, University of Massachusetts Medical School, Worcester, MA 01605, USA.
Shaoyong LiHorae Gene Therapy Center, University of Massachusetts Medical School, Worcester, MA 01605, USA.
Dominic J GesslerHorae Gene Therapy Center, University of Massachusetts Medical School, Worcester, MA 01605, USA.
Jun XieHorae Gene Therapy Center, University of Massachusetts Medical School, Worcester, MA 01605, USA.
Li ZhongHorae Gene Therapy Center, University of Massachusetts Medical School, Worcester, MA 01605, USA.
Jia LiHorae Gene Therapy Center, University of Massachusetts Medical School, Worcester, MA 01605, USA.
Karen TranHorae Gene Therapy Center, University of Massachusetts Medical School, Worcester, MA 01605, USA.
Kim Van VlietDepartment of Biochemistry and Molecular Biology, University of Florida, Gainesville, FL 32610, USA.
Lingzhi RenHorae Gene Therapy Center, University of Massachusetts Medical School, Worcester, MA 01605, USA.
Qin SuViral Vector Core, University of Massachusetts Medical School, Worcester, MA 01605, USA.
Ran HeViral Vector Core, University of Massachusetts Medical School, Worcester, MA 01605, USA.
Jason E GoetzmannNew Iberia Research Center, University of Louisiana at Lafayette, New Iberia, LA 70560, USA.
Terence R FlotteHorae Gene Therapy Center, University of Massachusetts Medical School, Worcester, MA 01605, USA.
Mavis Agbandje-McKennaDepartment of Biochemistry and Molecular Biology, University of Florida, Gainesville, FL 32610, USA.
Guangping GaoHorae Gene Therapy Center, University of Massachusetts Medical School, Worcester, MA 01605, USA.
University of Massachusetts Chan Medical School · USUniversity of Florida · USUniversity of Louisiana at Lafayette · US

Funding

Viral escape from AAV expressed transgenesP01AI100263 · NIAID · SCRIPPS FLORIDA · PI FARZAN, MICHAEL R. · 2012 to 2016
$11.9M
Viral Vector CoreP01HL131471 · NHLBI · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI FLOTTE, TERENCE R. · 2016 to 2020
$11.3M
Structural studies of AAV capsids and their glycan receptor interactionsR01GM082946 · NIGMS · UNIVERSITY OF FLORIDA · PI ROBERT MCKENNA · 2007 to 2026
$6.1M
Oligodendrocyte-focused rAAV gene therapy strategies for Canavan disease and LeukodystrophiesR01NS076991 · NINDS · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI Guangping Gao · 2012 to 2026
$5.7M
Next Generation of Recombinant AAV Serotype Vectors for Gene TherapyR01HL097088 · NHLBI · UNIVERSITY OF FLORIDA · PI GAO, GUANGPING, HERZOG, ROLAND W. · 2010 to 2018
$5.4M
NHLBI NIH HHS P01 HL131471NHLBI NIH HHS R01 HL097088NIAID NIH HHS P01 AI100263NIGMS NIH HHS R01 GM082946NINDS NIH HHS R01 NS076991
6 · The paper itself

Abstract

Adeno-associated virus (AAV) has provided the gene therapy field with the most powerful

Indexed as

AAV capsidadeno-associated virusCNS diseasegene therapytissue detargeting

Identifiers

PMID29766031
PMCPMC5948233
OpenAlexW2793963983

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.